ATORX — Alligator Bioscience AB Income Statement
0.000.00%
Last trade - 00:00- SEK138.83m
- SEK118.10m
- SEK57.77m
Annual income statement for Alligator Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.35 | 12.9 | 35.7 | 58.1 | 57.8 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 149 | 155 | 228 | 307 | 287 |
| Operating Profit | -144 | -142 | -193 | -249 | -229 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -143 | -142 | -193 | -249 | -234 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -143 | -142 | -193 | -249 | -234 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -143 | -142 | -193 | -249 | -234 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -143 | -142 | -193 | -249 | -234 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -90.4 | -958 | -44.9 | -46.9 | -26.9 |
| Dividends per Share |